Nakao A, Nonami T, Harada A, Kasuga T, Takagi H
Second Department of Surgery, Nagoya University School of Medicine, Japan.
Surgery. 1990 Nov;108(5):913-8.
Curative resection of pancreatic and hepatobiliary tumors is rarely possible because of local invasion, especially into the portal vein. We developed a new antithrombogenic catheter using a heparinized hydrophilic polymer to allow portal vein bypass during resection of tumors invading the portal vein. Pancreatectomy or hepatectomy accompanied by portal vein resection was performed for pancreatic or hepatobiliary cancer, with an intraoperative shunt from the superior mesenteric vein to the femoral vein or from the superior mesenteric vein to the intrahepatic portal vein through the umbilical vein or the hepatic hilar portal vein. Use of the shunt prevented stasis in the superior mesenteric vein and hepatic ischemia even during prolonged occlusion of the portal vein, and portal vein resection was performed in 81 patients with hepatobiliary and pancreatic disease with greater safety and ease.
由于局部侵犯,尤其是侵犯门静脉,胰腺和肝胆肿瘤很少能够进行根治性切除。我们研发了一种使用肝素化亲水性聚合物的新型抗血栓形成导管,以便在切除侵犯门静脉的肿瘤时实现门静脉分流。对胰腺癌或肝胆癌患者实施了伴有门静脉切除的胰切除术或肝切除术,术中通过肠系膜上静脉至股静脉或经脐静脉或肝门门静脉从肠系膜上静脉至肝内门静脉进行分流。即使在门静脉长时间闭塞期间,使用分流装置也可防止肠系膜上静脉发生淤滞和肝脏缺血,并且81例患有肝胆和胰腺疾病的患者在更安全、更轻松的情况下接受了门静脉切除术。